Food Allergy Immunotherapy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Food Allergy Immunotherapy remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 289 matched trial records and 161 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07701954 | LCA-0061 | Phase 1; Recruiting | Lycia Therapeutics, Inc. | Canada | Occurrence of treatment-emergent adverse events (TEAEs) (Part A (SAD) Cohorts: Day 1 up to Day 36 - Part B (MAD) Cohorts: Day 1 up to…); Occurrence of TEAEs leading to discontinuation (Part A (SAD) Cohorts: Day 1 up to Day 36 - Part B (MAD) Cohorts: Day 1 up to…) | 2028-04-01 |
| NCT07687797 | Intervention not normalized | Not Applicable; Not yet recruiting | Ain Shams University | Egypt | determining the frequency of cow milk intolerance diagnosis among patients suspected for cow milk protein allergy (12 weeks) | 2027-08-01 |
| JPRN-jRCT1030260236 | Intervention not normalized | Phase 1; 募集前 | Sponsor not listed | Japan | Overall acceptability; 総合評価 | 2026-07-20 |
| ChiCTR2600126340 | Intervention not normalized | Not Applicable; Not yet recruiting | Zhongshan People's Hospital | China | Development of milk protein tolerance by the end of follow-up | 2028-04-01 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy (Phase 2): the indexed record reports Percentage of Participants Who Tolerated a Single Dose of >= 600 mg (1044 mg Cumulative Tolerated Dose) of Peanut Protein Without Dose-limiting Symptoms = 0.0 percentage of participants; Percentage of Participants Who Tolerated a Single Dose of >= 600 mg (1044 mg Cumulative Tolerated Dose) of Peanut Protein Without Dose-limiting Symptoms = 50.0 percentage of participants; Percentage of Participants Who Tolerated a Single Dose of >= 600 mg (1044 mg Cumulative Tolerated Dose) of Peanut Protein Without Dose-limiting Symptoms: Difference in Marginal Response Rate = 0.34(80% CI, 0.17 - 0.51); Posterior Probability = 0.989; Difference in Marginal Response Rate = 0.45(80% CI, 0.27 - 0.62); Posterior Probability = 0.997; Difference in Marginal Response Rate = 0.77(80% CI, 0.61 - 0.90); Posterior Probability = 1.000.
- Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes (Phase 2): the indexed record reports The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC) = 3 Participants; The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC): Odds Ratio (OR) = 1.9(95% CI, 0.8 - 4.7), P-Value = 0.16; The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC): Odds Ratio (OR) = 1.9(95% CI, 0.8 - 4.7), P-Value = 0.16.
- Immunonutritional effects elicited by a novel multicomponent food supplement in children with cow's milk allergy: results from a randomized, placebo-controlled trial (Phase 2): the indexed record reports Height(6-month) = 90.0 cm; -.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including LCA-0061 (Phase 1; IgE). Company & Deal Intelligence records identify sponsor context for Lycia Therapeutics, Inc., Ain Shams University, Zhongshan People's Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Food Allergy Immunotherapy has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
